Congratulations to France PIRENNE and Renaud TISSIER, new members of the French National Academy of Medicine, to Alexandre BOISSONNAS’ team for obtaining funding from the ARC Foundation, and to Pablo BARTOLUCCI’s team for its publication in NEJM Evidence.

France PIRENNE and Renaud TISSIER newly elected to the National Academy of Medicine

 

Congratulations to France PIRENNE, BARTOLUCCI team, and Renaud TISSIER, GHALEH team, who were both appointed members of the National Academy of Medicine during the formal opening session held on Tuesday, January 6.
France PIRENNE in the Medicine and Medical Specialties division, and Renaud TISSIER in the Health division.

This appointment is a remarkable recognition of the quality of their scientific careers and their commitment. It also contributes to the reputation of the Mondor Institute within this prestigious institution.

 

Congratulations to the BOISSONNAS team on receiving €70k in funding from the ARC Foundation (PJA 2026), enabling the launch of a brand new team research project on the role of androgens in the polarization of macrophages in prostate cancer.

 

Alexandre BOISSONNAS, Francis VACHEROT: “This project is based on the notion of the regulation of the immune system by sex hormones. This concept plays a major role today in questioning the ‘gender effect’ on susceptibility to diseases, particularly cancer. Beyond the effect of hormones on tumor cells, we believe that androgens play an important role in the regulation of macrophages. The objectives of our project are to better characterize the molecular mechanisms involved, in particular the expression profile of the immune checkpoints PDL1, CD80, and CD86 by macrophages associated with prostate tumors. The ultimate goal of this project is to develop an innovative therapy combining immunotherapy and hormone therapy to control the progression of prostate cancer.

 

Congratulations to the BARTOLUCCI team, which has just published an article in the journal NEJM Evidence.

 

This international prospective study validated the PRESEV score, based on routine clinical and biological criteria, as a predictive tool for acute chest syndrome risk in adults with sickle cell disease hospitalized for vaso-occlusive crisis.
In a cohort of 393 patients recruited in Africa and Europe, the score showed strong predictive performance: only 6% of low-risk patients (score ≤ 5) developed ATS, and there were no deaths in this group.
The results were reproducible across continents. An independent cohort of 100 low-risk patients treated on an outpatient basis via the DREPADOM system confirmed these data, with only one case of ATS observed.
These results suggest that the PRESEV score could be a useful tool for identifying patients at low risk of ATS and guiding management strategies.